OBJECTIVE: Therapeutic advances have improved survival in patients with myeloma (MM) over the past decade. We investigated whether survival has also improved in critically ill myeloma patients. DESIGN: Retrospective study. SETTING: Intensive care unit. PATIENT: Consecutive myeloma patients admitted to a teaching hospital ICU between 1990 and 2006. We compared three year-of-admission groups (1990-1995, 1996-2001, and 2002-2006) that matched changes in myeloma treatment (chemotherapy only, stem cell transplantation, and new molecules, respectively). INTERVENTION: None. MEASUREMENTS AND MAIN RESULTS: We included 196 patients. Reasons for ICU admission and patient characteristics were similar across groups; however, less use of conventional chemotherapy and radiotherapy and greater use of steroids were noted in the more recent periods. Over time, vasopressors and invasive mechanical ventilation were used decreasingly, and noninvasive ventilation increasingly, to treat acute respiratory failure. Hospital mortality decreased from 75% in 1990-1995 to 49% in 1996-2001 and 40% in 2002-2006 (P = 0.0007). Mortality was associated with poor performance status [OR 2.27, 95% CI (1.04-4.99)], need for mechanical ventilation [OR 4.33, 95% CI (1.86-10.10)], need for vasopressors [OR 2.57, 95% CI (1.12-5.86)], and admission for an event related to myeloma progression [OR 2.77, 95% CI (1.13-6.79)]. ICU admission within 48 h after hospital admission was associated with lower mortality [OR 0.28, 95% CI (0.19-0.89)]. CONCLUSION: Hospital mortality decreased significantly over the last 15 years in myeloma patients admitted to the ICU. Risk factors for death were organ failure and poor chronic health status. Early ICU admission was associated with lower mortality, suggesting opportunities for further improving survival.
OBJECTIVE: Therapeutic advances have improved survival in patients with myeloma (MM) over the past decade. We investigated whether survival has also improved in critically ill myelomapatients. DESIGN: Retrospective study. SETTING: Intensive care unit. PATIENT: Consecutive myelomapatients admitted to a teaching hospital ICU between 1990 and 2006. We compared three year-of-admission groups (1990-1995, 1996-2001, and 2002-2006) that matched changes in myeloma treatment (chemotherapy only, stem cell transplantation, and new molecules, respectively). INTERVENTION: None. MEASUREMENTS AND MAIN RESULTS: We included 196 patients. Reasons for ICU admission and patient characteristics were similar across groups; however, less use of conventional chemotherapy and radiotherapy and greater use of steroids were noted in the more recent periods. Over time, vasopressors and invasive mechanical ventilation were used decreasingly, and noninvasive ventilation increasingly, to treat acute respiratory failure. Hospital mortality decreased from 75% in 1990-1995 to 49% in 1996-2001 and 40% in 2002-2006 (P = 0.0007). Mortality was associated with poor performance status [OR 2.27, 95% CI (1.04-4.99)], need for mechanical ventilation [OR 4.33, 95% CI (1.86-10.10)], need for vasopressors [OR 2.57, 95% CI (1.12-5.86)], and admission for an event related to myeloma progression [OR 2.77, 95% CI (1.13-6.79)]. ICU admission within 48 h after hospital admission was associated with lower mortality [OR 0.28, 95% CI (0.19-0.89)]. CONCLUSION: Hospital mortality decreased significantly over the last 15 years in myelomapatients admitted to the ICU. Risk factors for death were organ failure and poor chronic health status. Early ICU admission was associated with lower mortality, suggesting opportunities for further improving survival.
Authors: Dominique D Benoit; Pieter O Depuydt; Koenraad H Vandewoude; Fritz C Offner; Tom Boterberg; Carole A De Cock; Lucien A Noens; Ann M Janssens; Johan M Decruyenaere Journal: Intensive Care Med Date: 2005-11-25 Impact factor: 17.440
Authors: Vincent Lévy; Sandrine Katsahian; Jean Paul Fermand; Jean Yves Mary; Sylvie Chevret Journal: Medicine (Baltimore) Date: 2005-07 Impact factor: 1.889
Authors: Márcio Soares; Jorge I F Salluh; Marilia S Carvalho; Michael Darmon; José R Rocco; Nelson Spector Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Jae-Uk Song; Gee Young Suh; Hye Yun Park; So Yeon Lim; Seo Goo Han; Yeh Rim Kang; O Jung Kwon; Sookyoung Woo; Kyeongman Jeon Journal: Intensive Care Med Date: 2012-05-17 Impact factor: 17.440
Authors: François Vincent; Sondes Yaacoubi; Abdelaziz Bouguerba; Soufia Ayed; Caroline Bornstain Journal: Support Care Cancer Date: 2017-03-18 Impact factor: 3.603
Authors: I Suárez; B Böll; A Shimabukuro-Vornhagen; G Michels; M von Bergwelt-Baildon; M Kochanek Journal: Med Klin Intensivmed Notfmed Date: 2015-05-21 Impact factor: 0.840
Authors: Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares Journal: Intensive Care Med Date: 2017-07-19 Impact factor: 17.440
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-01-08 Impact factor: 17.440